TWI658049B - Ｋｎｔｃ２胜肽及含此胜肽之疫苗 - Google Patents

Ｋｎｔｃ２胜肽及含此胜肽之疫苗 Download PDF

Info

Publication number
TWI658049B
TWI658049B TW103107588A TW103107588A TWI658049B TW I658049 B TWI658049 B TW I658049B TW 103107588 A TW103107588 A TW 103107588A TW 103107588 A TW103107588 A TW 103107588A TW I658049 B TWI658049 B TW I658049B
Authority
TW
Taiwan
Prior art keywords
peptide
antigen
cells
present
kntc2
Prior art date
Application number
TW103107588A
Other languages
English (en)
Chinese (zh)
Other versions
TW201443077A (zh
Inventor
角田卓也
Takuya Tsunoda
大沢龍司
Ryuji Osawa
吉村祥子
Sachiko Yoshimura
渡辺朝久
Tomohisa Watanabe
Original Assignee
腫瘤療法 科學股份有限公司
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 腫瘤療法 科學股份有限公司, Oncotherapy Science, Inc. filed Critical 腫瘤療法 科學股份有限公司
Publication of TW201443077A publication Critical patent/TW201443077A/zh
Application granted granted Critical
Publication of TWI658049B publication Critical patent/TWI658049B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW103107588A 2013-03-12 2014-03-06 Ｋｎｔｃ２胜肽及含此胜肽之疫苗 TWI658049B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777334P 2013-03-12 2013-03-12
US61/777,334 2013-03-12

Publications (2)

Publication Number Publication Date
TW201443077A TW201443077A (zh) 2014-11-16
TWI658049B true TWI658049B (zh) 2019-05-01

Family

ID=51536362

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103107588A TWI658049B (zh) 2013-03-12 2014-03-06 Ｋｎｔｃ２胜肽及含此胜肽之疫苗

Country Status (17)

Country Link
US (1) US9597382B2 (https=)
EP (1) EP2970944B1 (https=)
JP (1) JP6295491B2 (https=)
KR (1) KR102213574B1 (https=)
CN (1) CN105164256B (https=)
AR (1) AR095386A1 (https=)
AU (1) AU2014232630B2 (https=)
BR (1) BR112015021828A2 (https=)
CA (1) CA2903139C (https=)
DK (1) DK2970944T3 (https=)
ES (1) ES2739693T3 (https=)
IL (1) IL240701B (https=)
MX (1) MX366365B (https=)
RU (1) RU2671395C2 (https=)
SG (2) SG10201707316WA (https=)
TW (1) TWI658049B (https=)
WO (1) WO2014141683A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681899C (en) 2007-03-27 2018-06-19 Immunovia Ab Methods for diagnosis of pancreatic adenocarcinoma, and biomarkers and arrays for use in the same
CA2974261A1 (en) * 2015-02-09 2016-08-18 Universite De Montreal Novel minor histocompatibility antigens and uses thereof
ES2960205T3 (es) 2015-06-16 2024-03-01 Fond Citta Della Speranza Onlus Vesículas extracelulares derivadas de células del linaje osteoblástico para uso terapéutico y diagnóstico
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
EP4649954A3 (en) 2017-01-25 2025-12-17 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
EP4036235A1 (en) * 2018-02-15 2022-08-03 National University Corporation Asahikawa Medical University Cancer antigen peptide
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
US20230374140A1 (en) * 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200844111A (en) * 2007-02-21 2008-11-16 Oncotherapy Science Inc Peptide vaccines for cancers expressing tumor-associated antigens

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
WO1998045433A1 (en) 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20020102542A1 (en) * 1997-10-07 2002-08-01 Daikichi Fukushima Polypeptide, cdna encoding the polypeptide, and use of the both
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ES2747357T3 (es) 2001-03-14 2020-03-10 Dako Denmark As Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004055050A2 (en) 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
JP2006517788A (ja) 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
EP1651775A2 (en) 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN1898563B (zh) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
EP1856278A2 (en) 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US8349555B2 (en) * 2005-03-16 2013-01-08 Gennadi V. Glinsky Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
EP1915622A2 (en) 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US7507536B2 (en) * 2005-10-07 2009-03-24 The Johns Hopkins University Methylation markers for diagnosis and treatment of ovarian cancer
WO2007064743A2 (en) 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP5576610B2 (ja) * 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
ES2487637T3 (es) 2006-04-10 2014-08-22 Genentech, Inc. Moduladores de PDZ Disheveled
ES2632123T3 (es) 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
US9273100B2 (en) * 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
WO2009099580A2 (en) * 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010115141A2 (en) * 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CA2775978A1 (en) 2009-09-29 2011-04-07 Protagen Ag Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof
BR112015023752B1 (pt) * 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
US11069427B2 (en) * 2013-06-10 2021-07-20 Iogenetics, Llc Mathematical processes for determination of peptidase cleavage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200844111A (en) * 2007-02-21 2008-11-16 Oncotherapy Science Inc Peptide vaccines for cancers expressing tumor-associated antigens

Also Published As

Publication number Publication date
KR20150126390A (ko) 2015-11-11
CN105164256A (zh) 2015-12-16
SG10201707316WA (en) 2017-10-30
TW201443077A (zh) 2014-11-16
BR112015021828A2 (pt) 2017-08-29
EP2970944A1 (en) 2016-01-20
HK1214838A1 (en) 2016-08-05
US20160008445A1 (en) 2016-01-14
DK2970944T3 (da) 2019-07-22
JP2016511221A (ja) 2016-04-14
EP2970944B1 (en) 2019-05-08
AU2014232630A1 (en) 2015-09-17
RU2015143164A (ru) 2017-04-13
AU2014232630B2 (en) 2020-07-09
EP2970944A4 (en) 2017-04-19
MX366365B (es) 2019-07-05
CA2903139A1 (en) 2014-09-18
US9597382B2 (en) 2017-03-21
CA2903139C (en) 2022-07-26
CN105164256B (zh) 2018-10-19
JP6295491B2 (ja) 2018-03-20
KR102213574B1 (ko) 2021-02-09
SG11201507236XA (en) 2015-10-29
AR095386A1 (es) 2015-10-14
IL240701A0 (en) 2015-10-29
MX2015012012A (es) 2016-04-07
RU2671395C2 (ru) 2018-10-30
IL240701B (en) 2022-02-01
WO2014141683A1 (en) 2014-09-18
ES2739693T3 (es) 2020-02-03

Similar Documents

Publication Publication Date Title
TWI658049B (zh) Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US9045557B2 (en) NEIL3 peptides and vaccines including the same
TWI617582B (zh) Ｔｏｐｋ胜肽及含其之疫苗
TWI485245B (zh) 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
TWI632162B (zh) Ｕｂｅ２ｔ胜肽與含此之疫苗
TWI564303B (zh) Ｍｐｈｏｓｐｈ１胜肽及含其之疫苗
TW201302800A (zh) Ｓｅｍａ５ｂ胜肽及含其之疫苗
RU2531348C2 (ru) Пептиды ттк и вакцины, их содержащие
TWI618541B (zh) Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
CN103189510B (zh) Ttll4肽及包含它们的疫苗
US8697631B2 (en) TMEM22 peptides and vaccines including the same
CN103282494B (zh) C18orf54肽及包含它们的疫苗
CN103270156B (zh) Wdhd1肽及包含它们的疫苗
TW201431874A (zh) Ｓｅｍａ５ｂ胜肽與含此之疫苗
TW201443078A (zh) Ｃ１２ｏｒｆ４８胜肽及含此胜肽之疫苗
TW201439114A (zh) Ｃｄｃａ５胜肽及含此胜肽之疫苗
TW201512223A (zh) Ｓｍｙｄ３胜肽及含此之疫苗

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees